478 results on '"McMeekin, D."'
Search Results
2. A phase 1b dose escalation study of ipafricept (OMP[sbnd]54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer
3. The pro-inflammatory effect of obesity on high grade serous ovarian cancer
4. Primary and acquired platinum-resistance among women with high grade serous ovarian cancer
5. Initiation of a formalized precision medicine program in gynecologic oncology
6. Associations between etiologic factors and mortality after endometrial cancer diagnosis: The NRG Oncology/Gynecologic Oncology Group 210 trial
7. A phase I study of IV doxorubicin plus intraperitoneal (IP) paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure (GOG 9920): An NRG Oncology/Gynecologic Oncology Group study
8. A phase II trial of brivanib in recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study
9. The survival detriment of venous thromboembolism with epithelial ovarian cancer
10. Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer
11. Preface
12. Contributors
13. Sarcoma of the Uterus
14. Phase II trial of vaginal cuff brachytherapy followed by chemotherapy in early stage endometrial cancer patients with high-intermediate risk factors
15. Referrals to phase I clinical trials in a gynecologic oncology unit
16. Dynamic Contrast-Enhanced MR Imaging for Predicting Tumor Control in Patients with Cervical Cancer
17. Inpatient versus outpatient management of neutropenic fever in gynecologic oncology patients: Is risk stratification useful?
18. Etiologic heterogeneity in endometrial cancer: Evidence from a Gynecologic Oncology Group trial
19. Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence
20. A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study
21. A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: A Gynecologic Oncology Group study
22. A phase I study of intraperitoneal nanoparticulate paclitaxel (Nanotax®) in patients with peritoneal malignancies
23. A phase I study of concurrent weekly topotecan and cisplatin chemotherapy with whole pelvic radiation therapy in locally advanced cervical cancer: A gynecologic oncology group study
24. Relationships of Tubal Ligation to Endometrial Carcinoma Stage and Mortality in the NRG Oncology/Gynecologic Oncology Group 210 Trial
25. Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study
26. Phase II trial of intraperitoneal cisplatin combined with intravenous paclitaxel in patients with ovarian, primary peritoneal and fallopian tube cancer
27. A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group Study
28. Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: A Gynecologic Oncology Group study
29. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study
30. A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology
31. Stage IVB endometrial cancer: Does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis
32. Phase I trial of the treatment of high-risk endometrial cancer with concurrent weekly paclitaxel and cisplatin and whole abdominal radiation therapy: A Gynecologic Oncology Group study
33. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass
34. Ovarian cancer in the octogenarian: Does the paradigm of aggressive cytoreductive surgery and chemotherapy still apply?
35. Extraperitoneal para-aortic lymph node evaluation for cervical cancer via pfannenstiel incision: Technique and peri-operative outcomes
36. Comparison of outcome measures in patients with advanced squamous cell carcinoma of the vulva treated with surgery or primary chemoradiation
37. A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: A gynecologic oncology group study
38. Pathologic findings and outcomes for octogenarians presenting with uterine malignancy
39. Gynecologic Oncology Group risk groups for vulvar carcinoma: Improvement in survival in the modern era
40. Vesicovaginal fistula formation in patients with Stage IVA cervical carcinoma
41. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: A Gynecologic Oncology Group study
42. A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: A Gynecologic Oncology Group study
43. Targeted therapies for gynecologic malignancies
44. Endometrial cancer: Treatment of nodal metastases
45. Preface
46. The Adnexal Mass
47. Sarcoma of the Uterus
48. Contributors
49. Sequence dependence of hematologic toxicity using carboplatin and topotecan for primary therapy of advanced epithelial ovarian cancer: A phase I study of the Gynecologic Oncology Group
50. Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: A Gynecologic Oncology Group study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.